During the Covid-19 crisis, AMT Medical secures € 10 million of financing. Funding will be used to bring the ELANA™ Heart Bypass system to the market.
During the Covid-19 period, AMT Medical has gained trust in the ELANA innovation from a regional development fund Oost NL. Existing shareholders NextGen Ventures and Utrecht Holdings (UU/UMCU) are also financing this round. In total, AMT Medical has secured more than €10 million series A and non-dilutive funding to develop their easy to use, ‘best in class’ keyhole coronary bypass technology. A new standard, with lower costs for society, fewer complications, and a faster recovery for the patient.
Together with the St Antonius Hospital in Nieuwegein (Dr. B.P. (Bart) van PutteBart and Drs. P. (Patrick) Klein) and the UMC Utrecht (prof. dr. PAFM (Pieter A.) we are making big steps with our EFRO (“Operationeel Kansen voor West II”) grants. This gives us great help in the development of our unique technology with ELANA Heart Bypass to improve and simplify heart bypass operations. By improving bypass surgery with ELANA Heart Bypass, patients with coronary heart disease can return to their daily life more quickly. The simplification of the procedure makes minimally invasive bypass surgery accessible to patients around the world as many more cardiothoracic surgeons can perform them without a large learning curve thanks to ELANA Heart Bypass. Thanks to these enormous benefits, ELANA Heart Bypass has the potential to become the new standard for heart bypass surgery around the world.
June 2020 |First loan from Gelderland (a province of the Netherlands) innovation fund for medium-sized company. Innovation from AMT Medical improves the world of open heart surgery
We proudly announce that our KARDIO project is supported by a multimillion euro grant of “Operationeel Kansen voor West II” within the EFRO 2014-2020 program (Horizon 2020).
Next to the international recognition and significant financial support, we are proud to work together with our consortium members who are involved in the application and project.
January 2019 | Article from the Economic Board of Utrecht (in Dutch)
Augustus 2018 | Collaboration Deutsches Herzzentrum Berlin
Start collaboration with Prof. Dr. Volkmar Falk and Dr. Stephan Jacobs to prove our technique in the first patients.
July 2018 | Europe: "A paradigm shifting innovation"
Our ELANA heart (TECAB) project is ranked number 5 out of hundreds of European Grant applications (1 is the highest). Innovative companies from all markets and from over 35 countries could apply and were judged by an independent European expert committee who considered our project to be a “paradigm shifting innovation”.
Next to the international recognition and significant financial support, we are proud to work together with our consortium members who are involved in the application.
April 2018 | Collaboration St Antonius Nieuwegein
Start collaboration with Dr. Bart van Putte. His first PhD started at our Labs in september 2018.
March 2018 | Succesful finished study
After a succesfull pre-clinical study with 70 subjects, product optimilizations where made
February 2018 | MIT Subsidy assigned
Together with Xeltis in Eindhoven we receive the MIT grant/subsidy.
August 2017 | Philips buys our supplier
Philips buys Spectranetics, our partner in Catheter and Laser production. Since this take-over by Philips, they visit us on a regular basis to investigate collaboration.
June 2017 | Capital raise
Investment from NextGen Ventures (part of Noaber foundation) and Utrecht Holdings (part of UMCU and UU in Utrecht).
Earlier CE and FDA Elana Brain Bypass
AMT-Medical Headoffice Zonneoordlaan 17
6718 TK Ede
+31 30 32 00 345
AMT Medical Laboratory Yalelaan 52
3584 CM Utrecht